Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company's products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD). For acute circulatory support, the Company's product lines are CentriMag Acute Circulatory System (CentriMag) and for pediatric patients PediMag/PediVAS Acute Circulatory System (PediMag/PediVAS). HeartMate III, a centrifugal-flow, chronic, left ventricular assist system.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:THOR
- CUSIP: 88517530
- Web: www.thoratec.com/
- 50 Day Moving Avg: $63.03
- 200 Day Moving Avg: $51.62
- 52 Week Range: $25.04 - $63.51
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 39.44
- P/E Growth: 0.00
- Net Margins: 10.29%
- Return on Equity: 8.02%
- Return on Assets: 6.71%
- Average Volume: 1.51 million shs.
Frequently Asked Questions for Thoratec (NASDAQ:THOR)
What is Thoratec's stock symbol?
Thoratec trades on the NASDAQ under the ticker symbol "THOR."
How were Thoratec's earnings last quarter?
Thoratec Co. (NASDAQ:THOR) issued its earnings results on Tuesday, August, 4th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.28 by $0.09. The company earned $128.70 million during the quarter, compared to analysts' expectations of $115.48 million. Thoratec had a net margin of 10.29% and a return on equity of 8.02%. The business's revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.43 EPS. View Thoratec's Earnings History.
Who are some of Thoratec's key competitors?
Some companies that are related to Thoratec include Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), Boston Scientific Corporation (BSX), Koninklijke Philips N.V. (PHG), Intuitive Surgical (ISRG), Illumina (ILMN), Edwards Lifesciences Corporation (EW), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR) and Quidel Corporation (QDEL).
How do I buy Thoratec stock?
Shares of Thoratec can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Thoratec's stock price today?
MarketBeat Community Rating for Thoratec (NASDAQ THOR)MarketBeat's community ratings are surveys of what our community members think about Thoratec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Thoratec stock can currently be purchased for approximately $63.50.
Consensus Ratings for Thoratec (NASDAQ:THOR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Thoratec (NASDAQ:THOR)
(Data available from 9/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|12/3/2015||J P Morgan Chase & Co||Reiterated Rating||Neutral||$36.00 -> $43.00||N/A|
|11/2/2015||Leerink Swann||Boost Price Target||Outperform||$32.00 -> $45.00||N/A|
|11/2/2015||Canaccord Genuity||Boost Price Target||Buy||$39.00 -> $41.00||N/A|
|10/14/2015||Goldman Sachs Group, Inc. (The)||Upgrade||Hold||N/A|
|9/29/2015||BMO Capital Markets||Upgrade||Market Perform -> Outperform||$56.00 -> $60.00||N/A|
|9/25/2015||BTIG Research||Reiterated Rating||Neutral||N/A|
Earnings History for Thoratec (NASDAQ:THOR)Earnings History by Quarter for Thoratec (NASDAQ THOR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/4/2015||Q215||$0.28||$0.37||$115.48 million||$128.70 million||View||Listen|
|5/7/2015||Q115||$0.26||$0.38||$111.10 million||$121.31 million||View||Listen|
|2/10/2015||Q414||$0.24||$0.39||$106.90 million||$127.96 million||View||Listen|
|11/5/2014||Q314||$0.22||$0.18||$106.30 million||$105.80 million||View||Listen|
|8/6/2014||Q214||$0.43||$0.43||$128.30 million||$118.10 million||View||Listen|
|5/6/2014||Q114||$0.39||$0.41||$122.56 million||$125.70 million||View||Listen|
|2/4/2014||Q413||$0.41||$0.38||$128.47 million||$128.20 million||View||Listen|
|10/30/2013||Q313||$0.40||$0.49||$121.25 million||$126.40 million||View||Listen|
|7/31/2013||Q2 2013||$0.43||$0.52||$121.51 million||$130.50 million||View||Listen|
|5/2/2013||Q1 2013||$0.46||$0.41||$122.53 million||$117.73 million||View||Listen|
|2/5/2013||Q4 2012||$0.38||$0.38||$119.09 million||$128.50 million||View||Listen|
|11/1/2012||Q312||$0.39||$0.41||$111.80 million||$117.80 million||View||N/A|
Earnings Estimates for Thoratec (NASDAQ:THOR)
Current Year EPS Consensus Estimate: $1.37 EPS
Next Year EPS Consensus Estimate: $1.61 EPS
Dividend History for Thoratec (NASDAQ:THOR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Thoratec (NASDAQ:THOR)Insider Trades by Quarter for Thoratec (NASDAQ:THOR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/26/2015||Neil F Dimick||Director||Sell||8,173||$44.98||$367,621.54|| |
|5/15/2015||Paul A Laviolette||Director||Sell||5,668||$44.70||$253,359.60|| |
|4/10/2015||Neil F Dimick||Director||Sell||4,786||$43.00||$205,798.00|| |
|12/4/2014||J Daniel Cole||Director||Sell||5,000||$31.83||$159,150.00|| |
|5/27/2014||Neil F Dimick||Director||Sell||4,158||$32.15||$133,679.70|| |
|5/15/2014||Paul Laviolette||Director||Sell||6,023||$31.23||$188,098.29|| |
|3/10/2014||Gerhard Burbach||CEO||Sell||22,104||$36.53||$807,459.12|| |
|2/11/2014||Gerhard Burbach||CEO||Sell||20,000||$34.71||$694,200.00|| |
|1/15/2014||Gerhard Burbach||CEO||Sell||9,400||$38.10||$358,140.00|| |
|1/14/2014||Gerhard Burbach||CEO||Sell||30,600||$36.65||$1,121,490.00|| |
|12/10/2013||Gerhard Burbach||CEO||Sell||40,000||$38.15||$1,526,000.00|| |
|11/12/2013||Gerhard Burbach||CEO||Sell||100,000||$41.40||$4,140,000.00|| |
|10/28/2013||Gerhard F Burbach||CEO||Sell||15,000||$40.02||$600,300.00|| |
|10/17/2013||Gerhard F Burbach||CEO||Sell||9,600||$39.00||$374,400.00|| |
|10/14/2013||Gerhard Burbach||CEO||Sell||40,400||$38.17||$1,542,068.00|| |
|10/11/2013||David Aaron Lehman||SVP||Sell||21,889||$38.17||$835,503.13|| |
|5/28/2013||Neil F Dimick||Director||Sell||1,273||$31.58||$40,201.34|| |
|5/20/2013||Neil F Dimick||Director||Sell||1,250||$31.61||$39,512.50|| |
|5/13/2013||Neil F Dimick||Director||Sell||1,250||$33.93||$42,412.50|| |
|11/26/2012||Gerhard F Burbach||CEO||Sell||11,600||$38.09||$441,844.00|| |
|10/4/2012||David Aaron Lehman||SVP||Sell||12,300||$36.11||$444,153.00|| |
Headline Trends for Thoratec (NASDAQ:THOR)
Latest Headlines for Thoratec (NASDAQ:THOR)
Thoratec (THOR) Chart for Thursday, September, 21, 2017